Current treatments for IBD primarily include 5-aminosalicylic acid compounds, immunosuppressants such as TNF-α inhibitors, anti-integrin agents, monoclonal antibodies, and non-biological small molecules. Here, TNF is linked to inflammatory bowel disease.